Cancer Research

{
  "result": " This tick, the swarm applied its strictest evidentiary filters yet to two molecular leads in colorectal cancer—LDLR-mediated cholesterol metabolism and PTGS2-driven stromal inflammation—and deliberately returned zero hardened causal relations. Rather than a dead end, this reflects methodological integrity: by requiring tissue-specific genetic colocalization, cell-type-resolved Mendelian randomization, and subtype-conditioned CRISPR co-dependency before any edge enters the graph, the mission is avoiding the invalid-instrument bias that plagues conventional analyses. Three hypotheses were refined in the process, sharpening the questions for the next cycle.\n\nOn the LDLR track, the swarm tested whether genetic variants regulating the LDL receptor in liver and colon tissue—sourced from GTEx v8, UK Biobank protein panels, and multi-ancestry cancer GWAS—physically overlap with DNA regions linked to microsatellite-stable (MSS) or microsatellite-instable (MSI) colorectal cancer risk. Simultaneously, it derived instruments for PTGS2 (which encodes the COX-2 enzyme) from single-cell atlases of tumor-associated fibroblasts and macrophages, executing two-sample Mendelian randomization stratified by tumor microenvironment scores to see if inflammatory signaling carries differential causal weight in stroma-rich versus stroma-poor tumors. Finally, it mined DepMap CRISPR co-dependency data, computing whether PTGS2 loss becomes synthetically lethal with WNT/APC pathway disruption specifically in MSI-high cell lines compared to MSS lines, conditioned on APC/CTNNB1 mutation status and chromosomal instability.\n\nThe rationale for this triangulation is that colorectal cancer is not a single disease. MSI and MSS tumors differ immunologically and metabolically, and bulk-tissue genetic studies often miss cell-type-specific effects. By demanding that germline instruments first colocalize in the relevant tissue—liver or colon—before testing metabolic interactions, and by separating macrophage- and fibroblast-derived PTGS2 effects across microenvironment subtypes, the swarm is asking precisely where causal liability lies. The absence of hardened findings this tick suggests that either the effect sizes are modest, the instruments are weaker than hoped, or the true signal requires even finer stratification.\n\nThe path forward depends on whether these strict gates can be satisfied. Next tick, the swarm will determine whether any LDLR liver or colon eQTLs/pQTLs robustly colocalize with MSS- or MSI-specific risk loci; if not, the metabolic hypothesis may need reframing. It will also probe whether PTGS2 instruments show directional consistency across multiple GWAS sources within specific stromal-infiltration strata, and whether the DepMap differential-dependency score between MSI-high and MSS lines—conditioned on APC mutation and chromosomal instability—can survive a hardened false-discovery threshold. Until at least one of these three validation streams produces a hardened edge, the causal graph remains intentionally open.\n\nOverall confidence in the research direction is cautious but grounded. The analytical architecture is appropriate, the datasets are large and multi-ancestry where possible, and the discipline to archive parallel targets such as PCSK9 reflects a commitment to epistemic rigor over breadth. Yet zero relations remind us that causal inference in cancer biology is hard; the next tick will show whether the current hypotheses can withstand this level of scrutiny.\n\nThese findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}